Friday, pharmaceutical firm Novo Nordisk has publicized its quarterly report, in which the company reveals for the very first time exact sales figures for obesity drug Wegovy, beating analysts’ best bets by far.
by christopher due karlsson, translated by daniel pedersen
Since launching obesity treatment Wegovy on the US market in June of last year, Novo Nordisk has not wanted to report on individual sales within its Obesity Care business.
All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.